Bank of America Corporation vs Cardinal Health, Inc.: Strategic Comparison

This in-depth comparison examines Bank of America Corporation and Cardinal Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bank of America Corporation on its own, evaluating Cardinal Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bank of America Corporation and Cardinal Health, Inc. is widest.

On the headline numbers, Bank of America Corporation reports annual revenue of $113.1B against $254.2B for Cardinal Health, Inc., while their respective market capitalizations stand at $380.6B and $56.0B. Both Bank of America Corporation and Cardinal Health, Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Bank of America Corporation: Bank of America is a universal bank with $3.41T of assets at December 31, 2025, the second largest in the United States by that measure. It runs two businesses that look nothing alike. For roughly 69 million consumer and small business clients it is a retail bank: the branch on the corner, the checking account, the card and the mortgage. For companies, governments and institutional investors it is an investment bank and trading house operating as BofA Securities, with Merrill and the Private Bank managing $4.75T of client balances. Consumer Banking produced $43.7B of revenue in 2025, Global Wealth and Investment Management $24.9B, Global Banking $24.1B and Global Markets $24.1B.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Bank of America Corporation and Cardinal Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bank of America Corporation and Cardinal Health, Inc..

Bank of America Corporation business model: The model is a deposit-funded spread business layered with fee income. Consumer Banking gathers low-cost deposits and lends through mortgages, cards and auto loans, producing $43.7B of revenue in 2025 and $12.2B of net income. Global Wealth and Investment Management charges fees on $4.75T of client balances, including $2.18T of assets under management, for $24.9B of revenue. Global Banking lends to companies and sells treasury solutions, underwriting and advice, for $24.1B. Global Markets makes markets in rates, credit, currencies, commodities and equities, for $24.1B. Across the company, net interest income was $60.1B in 2025 and fees and commissions $39.4B, of which investment and brokerage services were $20.0B and investment banking fees $6.6B.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bank of America Corporation stack up against those of Cardinal Health, Inc..

Bank of America Corporation competitive advantage: Bank of America's advantage is cheap, sticky funding. It held $2.02T of deposits at December 31, 2025, much of it in transaction accounts, and the total deposit spread was 2.92 percent in 2025 against 2.77 percent in 2024. Scale compounds it: approximately 69 million consumer and small business clients, 3,628 financial centers across 38 states and the District of Columbia, about 15,000 ATMs, and digital platforms with 49 million active users including 41 million on mobile. Preferred Rewards ties card rewards, lending discounts and fee waivers to combined bank and Merrill balances, so consolidating assets pays more than moving them. Erica, the assistant launched in 2018, has handled more than 3.2 billion client interactions and keeps routine servicing inside the app.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Future prospects matter as much as current results. The growth strategies below explain how Bank of America Corporation and Cardinal Health, Inc. each plan to expand from here.

Bank of America Corporation growth strategy: Growth comes from deepening existing relationships rather than buying banks. Consumer Banking adds clients through digital channels, with 49 million active digital users and 41 million mobile users at the end of 2025, while the branch network is consolidated slowly, down 72 to 3,628 centers during the year, and rebuilt in selected metropolitan markets. Wealth management is the main fee engine: client balances rose 12 percent to $4.75T and assets under management reached $2.18T in 2025. Global Banking pairs commercial bankers with investment bankers to win mid-market mandates, and CashPro serves treasury clients in more than 145 jurisdictions. Preferred Rewards ties pricing to combined banking and Merrill balances so assets stay inside the company.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

A closer look at the financial trajectory of Bank of America Corporation and Cardinal Health, Inc. rounds out the comparison.

Bank of America Corporation: Bank of America earns in two streams. Net interest income was $60.1B in 2025 and noninterest income $53.0B, for total revenue net of interest expense of $113.1B and net income of $30.5B, or $3.81 per diluted share. Deposits of $2.02T funded $1.19T of loans and leases plus a $927.4B debt securities portfolio. Fees carried the year: investment and brokerage services rose $2.2B to $20.0B, investment banking fees rose to $6.6B, and market making fell $953M to $12.0B. Credit stayed contained, with the total consumer net charge-off ratio at 0.88 percent and the card ratio at 3.68 percent. The efficiency ratio improved to 61.65 percent from 63.12 percent, and common equity tier 1 capital was $201.4B, an 11.4 percent standardized ratio against a 10.0 percent minimum.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.